Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Imago Raises $80m Series C To Take Bomedemstat Into Phase III

Company Plans IPO In 2021 To Fund Additional Pivotal Trials

Executive Summary

The $80m financing will support a Phase III myelofibrosis study for the LSD1 inhibitor and earlier-stage programs, but additional late-stage studies will require an initial public offering, likely next year.

You may also be interested in...



Inrebic Approval Is A Boost For Myelofibrosis And Celgene's Buyer Bristol

Investors in Impact Biosciences, which sold the selective JAK2 inhibitor to Celgene for $1.1bn up front, could double their money with milestone fees based on fedratinib's approval.

Finance Watch: Flagship Raises $824m To Speed Growth Of Its Portfolio Companies

Private Company Edition: The VC firm and start-up factory Flagship Pioneering brings in new cash for existing investments, tapping into investors eager to back "big, bold platform ideas" in the life sciences. Also, new financings include $100m-plus deals for Harmony and Beam.

BioNotebook: Five VC deals, three public financings, and a round of layoffs

Syros raises $53m Series B; Aileron gets $33m more for Series E; Imago closes $26.5m Series A; $20m equity investment for Xcovery; Affinivax launches with $4m; Synergy sells convertible notes; Regulus, Vanda price stock offerings; and Impax cuts 49 jobs.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

OM006550

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel